![Alexander Polinsky](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alexander Polinsky
Directeur Général chez
Everon Biosciences, Inc.
Profil
Dr. Alexander Polinsky is Independent Director at AtheroNova, Inc., Venture Partner and Managing Partner at Maxwell Asset Management LLC.
Prior to joining Maxwell Asset Management LLC in December 2009, Dr. Polinsky was employed by Pfizer Inc., as Chief Executive Officer by The Pfizer Incubator, Vice President & Head-Discovery Technologies by Pfizer, Scientist by University of California and Chief Scientific Officer by Alanex Corp.
Dr. Polinsky received his MS in Chemistry and his PhD in Chemistry from Moscow University-Russia.
Postes actifs de Alexander Polinsky
| Sociétés | Poste | Début |
|---|---|---|
Maxwell Asset Management LLC (US)
 Maxwell Asset Management LLC (US) Investment ManagersFinance Maxwell Asset Management manages the Maxwell Biotech Venture Fund. The fund focuses on investments in the biotechnology and pharmaceutical sectors with emphasis on therapeutics, industrial biotechnology and agricultural/veterinary applications. Within the therapeutics industry, the Fund focuses on investments in clinical areas of oncology, diseases of the central nervous system and metabolic disorders. The Fund invests in the application of biotechnology for industrial purposes including the production of biofuels and industrial reagents. In addition, the Fund invests in the application of biotechnology to strategically important agricultural products, such as plant growth promoters, crop protectors and animal health products. The Fund invests in public and private companies in North America, Europe and other parts of the world. Maxwell looks for companies: (1) that are developing products and technologies that are synergistic with the Fund's existing portfolio companies (2) with products that can benefit from testing in Russian clinical trial centers and (3) are interested in commercializing innovative therapeutics in the Russian market. The Maxwell Biotech Venture Fund's primary goal is to invest in Russian-based companies that are developing innovative products and technologies for the domestic and global markets. Maxwell also works with and invests in Western companies when they can help them advance their products along the development path, bring innovative products to the Russian market and generate superior return on investment. Typical investments range from $1 million to $10 million per company, depending on the stage of the company and its products. Maxwell is open to syndication with other venture firms. They place priority on investments that are likely to lead to a financial exit within 5 years. | Private Equity Investor | 01/10/2009 |
Maxwell Asset Management LLC (Private Equity)
 Maxwell Asset Management LLC (Private Equity) Investment ManagersFinance Maxwell Asset Management is an active manager which provides equity financing in companies located in Russia. The firm targets companies operating in the life sciences sector with a focus on biotechnology, therapeutics, and high-tech medical devices. It invests in early-stage capital requirements with an investment amount of up to USD 5 million in a single company. | Private Equity Investor | - |
Everon Biosciences, Inc.
 Everon Biosciences, Inc. BiotechnologyHealth Technology Develops anti-aging medicines | Directeur Général | - |
Oncotartis, Inc.
 Oncotartis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Directeur Général | 01/01/2011 |
Anciens postes connus de Alexander Polinsky
| Sociétés | Poste | Fin |
|---|---|---|
| STATERA BIOPHARMA, INC. | Directeur/Membre du Conseil | 14/04/2015 |
| PFIZER INC. | Corporate Officer/Principal | 30/06/2008 |
Pfizer (La Jolla)
 Pfizer (La Jolla) Miscellaneous Commercial ServicesCommercial Services Provides research services | Directeur Technique/Scientifique/R&D | 01/01/2008 |
The Pfizer Incubator LLC
 The Pfizer Incubator LLC Investment ManagersFinance Pfizer Incubator invests in companies located in North America, United States. | Directeur Général | 01/01/2008 |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 30/06/1999 |
Formation de Alexander Polinsky
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
95
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Alanex Corp.
 Alanex Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Cleveland BioLabs, Inc.
 Cleveland BioLabs, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to activate the immune system and address serious medical needs | Health Technology |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Moscow State University Lomonosov
 Moscow State University Lomonosov Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pfizer (La Jolla)
Pfizer (La Jolla) Miscellaneous Commercial ServicesCommercial Services Provides research services | Commercial Services |
Maxwell Asset Management LLC (US)
Maxwell Asset Management LLC (US) Investment ManagersFinance Maxwell Asset Management manages the Maxwell Biotech Venture Fund. The fund focuses on investments in the biotechnology and pharmaceutical sectors with emphasis on therapeutics, industrial biotechnology and agricultural/veterinary applications. Within the therapeutics industry, the Fund focuses on investments in clinical areas of oncology, diseases of the central nervous system and metabolic disorders. The Fund invests in the application of biotechnology for industrial purposes including the production of biofuels and industrial reagents. In addition, the Fund invests in the application of biotechnology to strategically important agricultural products, such as plant growth promoters, crop protectors and animal health products. The Fund invests in public and private companies in North America, Europe and other parts of the world. Maxwell looks for companies: (1) that are developing products and technologies that are synergistic with the Fund's existing portfolio companies (2) with products that can benefit from testing in Russian clinical trial centers and (3) are interested in commercializing innovative therapeutics in the Russian market. The Maxwell Biotech Venture Fund's primary goal is to invest in Russian-based companies that are developing innovative products and technologies for the domestic and global markets. Maxwell also works with and invests in Western companies when they can help them advance their products along the development path, bring innovative products to the Russian market and generate superior return on investment. Typical investments range from $1 million to $10 million per company, depending on the stage of the company and its products. Maxwell is open to syndication with other venture firms. They place priority on investments that are likely to lead to a financial exit within 5 years. | Finance |
AtheroNova, Inc.
 AtheroNova, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
The Pfizer Incubator LLC
The Pfizer Incubator LLC Investment ManagersFinance Pfizer Incubator invests in companies located in North America, United States. | Finance |
Maxwell Asset Management LLC (Private Equity)
Maxwell Asset Management LLC (Private Equity) Investment ManagersFinance Maxwell Asset Management is an active manager which provides equity financing in companies located in Russia. The firm targets companies operating in the life sciences sector with a focus on biotechnology, therapeutics, and high-tech medical devices. It invests in early-stage capital requirements with an investment amount of up to USD 5 million in a single company. | Finance |
OncoTartis LLC
 OncoTartis LLC BiotechnologyHealth Technology Engages in the development of anti-cancer drugs | Health Technology |
Everon Biosciences, Inc.
Everon Biosciences, Inc. BiotechnologyHealth Technology Develops anti-aging medicines | Health Technology |
Oncotartis, Inc.
Oncotartis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Health Technology |
